LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology enabled CRO dedicated to accelerating promising treatments, has collaborated with University of California at San ...

LONDON & CHICAGO, March 05, 2025--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), a technology-enabled CRO dedicated to accelerating promising treatments, has announced enrollment of the first two ...

LONDON & CHICAGO--(BUSINESS WIRE)--Anova Enterprises, Inc. (Anova), an organization dedicated to accelerating promising treatments to market with its transformative AnovaOS™ technology platform, has ...

Anova is managing the delivery of Phase 1/2a study of DB107 at UCSF, USC, UCSD and with Denovo Biopharma DB107 is a proprietary gene therapy platform for the treatment of patients with newly diagnosed ...

Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...

Denovo Biopharma LLC identified a novel genetic biomarker Denovo Genomic Marker 7 (DGM7 TM) based on data from a prior clinical trial in patients with recurrent disease believed to predict responders ...

Anova completed enrollment of 550+ patients for an intermediate-sized, treatment IND in just six months, significantly reducing traditional site activation and patient enrolment timelines, and ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...